TAA-06

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameTAA-06
Drug Alias NameTAA06-UCAR-γδTTAA-06
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursLung NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPersongen Biotherapeutics (Suzhou) Co LtdPersongen Anke Cell Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeuroblastoma
Inactive IndicationsLung NeoplasmsColorectal NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A